Market closed·Syncing…
Market closed · Close · 19 Nov

Orchid Pharma Limited ORCHPHARMAshare price and chart

Orchid Pharma closed at ₹948.60 on 19 November 2026, down 0.77% on the day. The 52-week range is ₹480.00 to ₹1,143.50.

₹948.60The price one share last traded at, in rupees.▼ 0.77% · ₹7.36
52-wk low ₹48071% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹1,144

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on ORCHPHARMA

Real prices, every charge counted. Pick one or write your own.
What Orchid Pharma Limited does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Orchid Pharma makes cephalosporin active pharmaceutical ingredients, 97% of its turnover, from six plants, for finished dosage makers, third-party job workers and brand makers in regulated and other markets across 52 countries. Exports are 64.5% of turnover.

1
1Sector

Pharmaceuticals & Biotechnology

2
2What it sells

Cephalosporin APIs

3
3Who buys it

Finished dosage makers, brand makers

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 19 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
57.6Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
24.8%Below average - weaker conviction
today 24.8%20d avg 44.2%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.+0.3%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.+15.1%1 monthHow much the share price has changed over the period.+7.0%3 monthsHow much the share price has changed over the period.▼ 3.1%1 yearHow much the share price has changed over the period.+18.8%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.44.8%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹5,681 Cr19 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.133.0xlast 4 quarters, to Sept 2026Return on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.0.7%full year FY26Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.3.48xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.1.2%full year FY26EV / EBITDAWhat it would cost to buy the whole company, against the cash profit its business makes in a year. It is a P/E that ignores how the company is financed.98.6xDividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.00%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.33xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.-21.4%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Pharmaceuticals · 141 peers · medians
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.133.04vs 32.6 median
Cheapest: WALPAR 7.92Priciest: COHANCE 510.5
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.3.69%vs 10.23% median
Lowest: MEDIORG -86.72%Highest: SHUKRAPHAR 38.89%
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.76.34%vs 20.87% median
Lowest: NECLIFE -99.78%Highest: SHUKRAPHAR 652.15%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 14 Nov 2026), sales rose 76.3% from a year earlier to ₹341 cr and profit turned positive at ₹28.6 cr after a loss of ₹5.7 cr a year earlier.

Going well
  • Sales grew 4 years running (₹560 cr in FY22 to ₹942 cr in FY26).
  • No promoter shares were pledged at the end of September 2026.
  • Promoter holding rose 4.6 points over 7 quarters (69.84% to 74.45%).
Worth watching
  • Operating margin fell from 12.6% in FY23 to 4.7% in FY26.
  • Return on equity stayed under 10% from FY24 to FY26 (highest 9.9%).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 19 results, the share rose on 6 and fell on 13, and moved by 3% or more on 12.

+24%
-24%
Q1 FY23Q1 FY24Q1 FY25Q1 FY26Q2 FY27

Q2 FY27: results filed 14 Nov 2026. The share went from its close on 13 Nov 2026 to its close on 16 Nov 2026 +4.51%.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
+18.6%a year, over 5 years
1 yr
+11.6%
3 yr
+21.9%
5 yr
+18.6%

Held for 5 years this compounded at +18.6% a year. The last twelve months were up +11.6%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
74.45%promoter holding, as of 2026-09-30-15.5 pts since 2021
Promoter share since listing
2021-0974.45% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
74.5%
17.4%
Promoter74.5%Foreign (FII)0.9%Domestic (DII)17.4%Public & others7.2%
Who is buying, who is leavingJun 25 to Sep 26
Promoter74.5%+4.6 pts
Foreign (FII)0.9%-0.5 pts
Domestic (DII)17.4%-2.0 pts

Each line is that holder's share of all shares over the last 7 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Promoter pledgeThe share of promoters' holdings given to lenders as security for a loan.0.00%of promoter shares, as at 2026-09-30

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Analysts/Institutional Investor Meet/Con. Call Updates17-Nov-2026

Orchid Pharma Limited has informed the Exchange about Link of Recording

Updates16-Nov-2026

Orchid Pharma Limited has informed the Exchange regarding 'Board comments on fine levied by the Exchange'.

Investor Presentation16-Nov-2026

Orchid Pharma Limited has informed the Exchange about Investor Presentation

Statement of deviation(s) or variation(s) under Reg. 3214-Nov-2026

Orchid Pharma Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32

Outcome of Board Meeting14-Nov-2026

Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Monitoring Agency Report13-Nov-2026

Monitoring Agency Report for Quarter-II ended on September 30,2026

Analysts/Institutional Investor Meet/Con. Call Updates12-Nov-2026

Orchid Pharma Limited has informed the Exchange about Schedule of meet

Press Release24-Oct-2026

Orchid Pharma Limited has informed the Exchange regarding a press release dated October 24, 2026, titled "Announcement under Regulation 30 regarding the licensing and supply agreement with Laboratorio Libra S.A.("Libra"}".

General Updates20-Oct-2026

Orchid Pharma Limited has informed the Exchange about General Updates

Outcome of Board Meeting20-Oct-2026

Orchid Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 20, 2026.

Certificate under SEBI (Depositories and Participants) Regulations, 201809-Oct-2026

Orchid Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Shareholders meeting01-Oct-2026

Orchid Pharma Limited has submitted the Exchange a copy Srutinizers report of 33rd Annual General Meeting held on September 29, 2026. Further, the company has informed the Exchange regarding voting results.

Shareholders meeting29-Sep-2026

Orchid Pharma Limited has informed the Exchange regarding Proceedings of the 33rd Annual General Meeting held on September 29, 2026

Trading Window28-Sep-2026

Orchid Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Updates23-Sep-2026

Orchid Pharma Limited has informed the Exchange regarding 'Trading Approval of Equity Shares issued and allotted under Scheme of Amalgamation'.

Backtest idea · ORCHPHARMAMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on ORCHPHARMA
Backtest idea · ORCHPHARMALower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on ORCHPHARMA
Backtest idea · ORCHPHARMASupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on ORCHPHARMA
Your own ideaWrite a rule for ORCHPHARMA in plain English“Buy ORCHPHARMA when …”
Start writing
Buy the dip on ORCHPHARMABuy when RSI(14) drops below 30
52-week high breakout on ORCHPHARMABuy when closes at a 52-week high
Golden cross on ORCHPHARMABuy when 50-day EMA crosses above 200-day
Stochastic oversold on ORCHPHARMABuy when stochastic %K drops below 20
Pullback in an uptrend on ORCHPHARMABuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹5,681 cr
Larger than 62% of 141 peers
sector middle ₹2,189 cr
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
133.0x
Higher than 97% of 118 peers
sector middle 32.6x
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
3.5x
Around the middle of 125 peers
sector middle 3.6x
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
0.7%
Lower than 85% of 109 peers
sector middle 12.4%
FY23 6.7%FY26 1.6%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
1.2%
Lower than 85% of 124 peers
sector middle 15.0%
FY23 8.6%FY26 1.2%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.33
Higher than 66% of 125 peers
sector middle 0.19
FY23 0.48FY26 0.19
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.0%
Lower than 56% of 141 peers
sector middle 0.1%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+76.3%
Higher than 89% of 130 peers
sector middle +20.9%
FY23 19.0%FY26 2.2%

Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY22FY23FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.4.7%FY26SalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹942 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹22 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹2.4 as profit. Other income added ₹3.8.

Where it wentPer ₹100 of sales
Running costs₹95.3Depreciation₹4.0Interest₹1.3Profit₹2.4Other items₹0.8
Profit per ₹100, year by year
FY22FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales+12.3%-+76.3%
Profit▼ 21.5%--
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash fell by ₹14 Cr, after ₹390 Cr spent on plant and equipment.

FY26Cash in or out
Running the business+₹126 Cr
Investing-₹277 Cr
Lenders and shareholders+₹137 Cr
Net change in cash-₹14 Cr
Operating cash per ₹100 of profit
₹40FY23₹137FY24₹19FY25₹1,261FY26
₹100 or more means the reported profit arrived as cash.

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY23FY24FY25FY26
Sales growthSales in this financial year against the previous one.19.0%23.1%12.5%2.2%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.12.6%13.4%11.7%4.7%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.7.0%11.2%10.8%2.4%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.6.7%9.9%8.2%1.6%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.8.6%9.3%8.0%1.2%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.48x0.11x0.14x0.19x
Interest coverHow many times the company's profit before interest could pay its interest bill.2.0x6.6x7.6x2.9x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · ORCHPHARMAStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on ORCHPHARMA
Backtest idea · ORCHPHARMAPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on ORCHPHARMA
Backtest idea · ORCHPHARMABuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on ORCHPHARMA
Backtest idea · ORCHPHARMA52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on ORCHPHARMA
Backtest idea · ORCHPHARMAGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on ORCHPHARMA
MACD momentum on ORCHPHARMABuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on ORCHPHARMABuy when closes below the lower Bollinger band
Supertrend rider on ORCHPHARMABuy when supertrend turns up
Buy the dip on ORCHPHARMABuy when RSI(14) drops below 30
52-week high breakout on ORCHPHARMABuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Pharmaceuticals
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
SUNPHARMA
Sun Pharmaceutical Industries Limited
4.56 L cr41.6x5.1x14.7%19.1%0.0317.8%+11.9%0.84%
DIVISLAB
Divi's Laboratories Limited
2.97 L cr88.2x16.5x16.2%21.5%0.0027.6%+35.4%0.27%
TORNTPHARM
Torrent Pharmaceuticals Limited
1.75 L cr77.9x9.6x17.0%15.2%0.7612.1%+50.8%0.82%
LAURUSLABS
Laurus Labs Limited
1.25 L cr92.9x20.6x17.7%17.9%0.4017.0%+33.4%0.10%
ZYDUSLIFE
Zydus Lifesciences Limited
1.20 L cr28.9x4.3x18.3%19.9%0.4414.1%+29.2%0.08%
DRREDDY
Dr. Reddy's Laboratories Limited
1.17 L cr41.7x3.0x11.5%13.9%0.158.3%-1.5%0.57%
CIPLA
Cipla Limited
1.15 L cr39.5x3.2x11.7%16.0%0.0110.1%-2.4%0.92%
MANKIND
Mankind Pharma Limited
1.09 L cr48.4x6.2x12.4%12.9%0.3014.7%+17.3%0.00%
AUROPHARMA
Aurobindo Pharma Limited
1.04 L cr26.2x2.6x9.9%12.8%0.2110.8%+23.9%0.39%
LUPIN
Lupin Limited
91,403 cr17.6x3.8x26.9%28.8%0.2317.0%+11.1%0.90%
GLENMARK
Glenmark Pharmaceuticals Limited
73,618 cr50.7x6.6x14.1%20.4%0.089.2%-31.3%0.10%
ALKEM
Alkem Laboratories Limited
61,516 cr29.8x4.1x17.6%20.6%0.1213.4%+13.8%1.03%
BIOCON
Biocon Limited
59,264 cr216.5x1.7x1.1%3.0%0.411.9%+2.2%0.14%
ABBOTINDIA
Abbott India Limited
54,600 cr33.0x----23.0%+11.0%2.55%
GLAND
Gland Pharma Limited
54,336 cr43.9x5.1x10.5%15.0%0.0217.5%+23.3%0.61%
IPCALAB
IPCA Laboratories Limited
47,189 cr33.6x5.4x13.2%16.6%0.0614.2%+13.8%0.32%
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
45,967 cr40.6x24.4x48.9%66.5%0.0027.6%+20.8%2.10%
EMCURE
Emcure Pharmaceuticals Limited
44,481 cr40.7x8.3x19.6%24.8%0.2710.7%+24.3%0.15%
AJANTPHARM
Ajanta Pharma Limited
40,865 cr32.4x8.4x25.4%32.7%0.0220.3%+32.5%0.98%
SAILIFE
Sai Life Sciences Limited
37,985 cr100.5x14.1x15.1%20.9%0.1715.9%+22.5%0.00%
WOCKPHARMA
Wockhardt Limited
35,537 cr86.7x6.9x4.0%6.5%0.3910.8%+23.9%0.00%
ACUTAAS
Acutaas Chemicals Limited
32,561 cr74.1x17.5x23.5%31.7%0.0027.5%+42.7%0.06%
PPLPHARMA
Piramal Pharma Limited
31,906 cr-3.9x-4.0%0.8%0.69-2.1%+28.1%0.00%
RUBICON
Rubicon Research Limited
28,510 cr87.3x20.1x19.1%23.4%0.2815.5%+39.9%0.09%
NEULANDLAB
Neuland Laboratories Limited
27,074 cr59.8x13.3x21.4%27.5%0.1719.6%-12.6%0.16%
APLLTD
Alembic Pharmaceuticals Limited
20,631 cr24.4x3.5x12.4%11.7%0.259.9%+36.3%1.14%
GRANULES
Granules India Limited
19,853 cr27.7x3.0x13.5%15.7%0.0912.1%+20.3%0.22%
ERIS
Eris Lifesciences Limited
18,418 cr25.8x4.4x18.1%13.9%0.5821.6%+12.6%0.54%
ONESOURCE
Onesource Specialty Pharma Limited
18,381 cr-3.1x-1.3%0.4%0.25-0.1%+37.4%0.00%
ALIVUS
Alivus Life Sciences Limited
17,801 cr26.6x4.9x18.4%24.6%0.0024.9%+16.0%0.34%
SHILPAMED
Shilpa Medicare Limited
17,616 cr52.7x6.4x9.8%11.4%0.2418.1%+43.0%0.07%
PFIZER
Pfizer Limited
17,614 cr20.5x4.0x17.2%23.4%0.0032.4%+13.2%1.95%
COHANCE
Cohance Lifesciences Limited
17,578 cr510.5x4.5x5.1%8.0%0.06-0.3%-14.2%0.00%
NATCOPHARM
Natco Pharma Limited
16,124 cr17.8x1.6x16.9%17.1%0.1126.9%-29.0%0.70%
CAPLIPOINT
Caplin Point Laboratories Limited
15,845 cr23.0x4.1x19.9%24.7%0.0029.4%+17.9%0.38%
ASTRAZEN
AstraZeneca Pharma India Limited
15,283 cr86.0x17.4x22.8%31.2%0.006.8%+30.4%0.59%
JUBLPHARMA
Jubilant Pharmova Limited
14,865 cr56.2x2.1x6.0%8.7%0.542.9%+20.5%0.54%
CORONA
CORONA Remedies Limited
13,680 cr66.1x17.0x24.8%27.8%0.1213.3%+22.2%0.45%
MARKSANS
Marksans Pharma Limited
13,556 cr24.2x4.1x25.4%35.1%0.0116.7%+30.5%0.30%
ORCHPHARMA
Orchid Pharma Limited
5,681 cr133.0x3.5x0.7%1.2%0.333.7%+76.3%0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-7.9
-11.3
-22.1
+29.7
+26.6
+22.8
+1.4
-1.6
+2.7
-16.1
+13.4
·
+25.0%
11m
2025
-21.8
-32.0
-19.2
+3.2
-21.5
+13.6
+3.6
-0.9
-4.4
+3.5
+14.7
-8.9
-58.0%
2024
+18.6
+40.0
-11.7
+3.2
-7.0
+13.6
+22.8
+8.7
-10.1
+6.6
+15.0
+7.8
+153.6%
2023
-5.3
+13.0
-1.6
+2.3
+6.2
+20.1
+14.5
-3.5
-3.7
-11.7
+21.1
+25.3
+95.7%
2022
-5.3
-26.9
+4.3
+26.1
-14.0
-8.2
+13.3
-3.8
+3.3
+21.3
+2.4
-8.4
-7.8%
2021
+164.6
+165.1
+178.5
-37.8
-4.8
-35.9
-50.6
-9.0
+3.5
-6.2
-0.8
-0.1
+220.4%
2020
·
·
·
·
·
·
·
·
·
·
·
+190.0
+190.0%
1m
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2025-05-30UTI MUTUAL FUND · bulkBUY3,66,507₹615.37₹22.55 Cr

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test ORCHPHARMA. “Buy ORCHPHARMA when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free